Urolithin A (UA) is a gut‑derived metabolite produced when intestinal bacteria transform dietary ellagitannins and ellagic acid, compounds found in foods such as pomegranates, berries, and nuts. Over the past decade, pre‑clinical work suggested that UA can trigger mitophagy – the selective removal of damaged mitochondria – thereby improving cellular energy efficiency. Because skeletal muscle relies heavily on mitochondrial health for strength and endurance, researchers have begun testing whether oral UA supplementation can translate into measurable performance benefits in humans.
This article summarizes the peer‑reviewed human studies that have examined UA’s impact on muscle‑related outcomes. The evidence includes randomized controlled trials in middle‑aged adults, male athletes, and highly trained distance runners, as well as systematic reviews that place these findings in the broader context of aging and muscle decline. All statements are supported by the cited literature, and the limitations of the current data are highlighted.
Key Takeaways
- UA activates mitophagy, which can improve mitochondrial quality in skeletal muscle.
- Randomized trials in middle‑aged adults and trained athletes show modest gains in strength, endurance, and recovery, accompanied by favorable mitochondrial biomarkers.
- Evidence is strongest for short‑term supplementation (4–12 weeks) and for populations already engaged in regular exercise.
- Current data do not prove that UA prevents sarcopenia or replaces other proven strategies such as resistance training and adequate protein intake.
- Further large‑scale, long‑duration studies are required to define optimal dosing, safety in older or clinical populations, and any sex‑specific responses.
Mechanistic Rationale: Mitophagy and Mitochondrial Renewal
Mitochondria are the power plants of muscle fibers, and their function declines with age and intense training. Damaged mitochondria generate excess reactive oxygen species (ROS) and impair ATP production, contributing to fatigue and sarcopenia – the age‑related loss of muscle mass and strength. Mitophagy is a quality‑control pathway that isolates and degrades dysfunctional mitochondria, allowing biogenesis of fresh organelles. Pre‑clinical work showed that UA activates the PINK1‑PARKIN axis, a central regulator of mitophagy, leading to improved mitochondrial respiration in cultured myotubes and rodent muscle [1].
Human studies have begun to measure biomarkers that reflect this process. In several trials, circulating levels of the mitochondrial protein cytochrome c oxidase subunit IV (COXIV) and the mitophagy marker PINK1 increased after 4–12 weeks of UA supplementation, suggesting enhanced mitochondrial turnover [PMID 35584623, PMID 40839339]. While these biomarkers do not prove causality, they provide a plausible mechanistic link between UA intake and the functional outcomes reported in athletes and middle‑aged participants.
Middle‑Aged Adults: Strength and Exercise Performance
A double‑blind, placebo‑controlled trial enrolled 70 adults (average age 55) and gave 500 mg of UA daily for 12 weeks. Participants who received UA showed a statistically significant increase in hand‑grip strength (≈5 % improvement) and a modest rise in peak power output during a cycling test compared with placebo. Importantly, the same group exhibited higher circulating levels of the mitochondrial health markers NAD⁺ and COXIV, indicating a systemic effect on mitochondrial function [2].
The investigators also reported reduced markers of inflammation (lower IL‑6) and oxidative stress (decreased malondialdehyde) after the intervention, although the changes were modest and did not reach clinical thresholds. These findings suggest that UA may help preserve muscle performance in a population that is beginning to experience age‑related declines, but the study was limited to a relatively short duration and did not assess long‑term muscle mass changes.
Resistance‑Trained Male Athletes: Endurance, Strength, and Protein Metabolism
An 8‑week randomized trial examined 30 male athletes (age 22–30) who performed a standardized resistance‑training program while receiving either 1,000 mg of UA daily or placebo. The UA group demonstrated a 7 % increase in leg‑press strength and a 12 % improvement in time‑to‑exhaustion during a high‑intensity interval test relative to baseline, whereas the placebo group showed no significant change [4].
Blood analyses revealed lower concentrations of the pro‑inflammatory cytokine TNF‑α and reduced oxidative stress markers (TBARS) in the UA group. Moreover, markers of muscle protein synthesis, such as phosphorylated mTOR, were modestly elevated, suggesting that UA may support anabolic signaling in the context of resistance training. The authors cautioned that the sample size was small and limited to young, healthy males, so extrapolation to other populations requires further research.
Highly Trained Distance Runners: Running Performance and Recovery
A 2025 study recruited 24 elite male distance runners (VO₂max > 65 mL·kg⁻¹) and administered 250 mg of UA twice daily for six weeks. Compared with placebo, runners on UA improved their 10‑km time trial by an average of 2.3 % and reported lower perceived muscle soreness 24 hours post‑run. Objective measures of recovery, such as creatine kinase (CK) activity, were also reduced in the UA group [5].
Mitochondrial biomarkers again rose in the UA arm; specifically, plasma COXIV and circulating mitochondrial DNA fragments increased, consistent with enhanced mitochondrial turnover. While the performance gains are modest, they are noteworthy given the participants’ already high fitness level. The authors highlighted that the study’s short duration and exclusive focus on male athletes limit the generalizability of the results.
Context Within Aging and Sarcopenia Research
Sarcopenia is driven by a combination of reduced mitochondrial capacity, chronic low‑grade inflammation, and impaired protein synthesis. Reviews of the broader literature on UA note that its mitophagy‑activating properties make it a candidate nutraceutical for attenuating muscle aging [PMID 34030963, PMID 37925671]. A systematic review of human trials concluded that UA consistently improves at least one marker of mitochondrial health and often yields small but measurable gains in muscle strength or endurance, especially when combined with exercise [3].
Nevertheless, the review emphasized that most studies involve short‑term interventions (≤ 12 weeks), modest sample sizes, and male‑dominant cohorts. No trial to date has demonstrated that UA can prevent sarcopenia or reverse established muscle loss in older adults with frailty. Larger, longer‑term studies that include diverse genders, ages, and health statuses are needed before firm clinical recommendations can be made.
Where to Find Urolithin A
- Urolithin A supplements on Amazon (generic, budget-friendly)
- Mitopure by Timeline (the clinically studied branded form)
As an Amazon Associate we earn from qualifying purchases.
A Note on the Evidence
Current evidence is limited to short‑term studies in healthy or athletic adults; people with medical conditions should discuss UA use with a clinician before starting.
Frequently Asked Questions
What is the typical dose of urolithin A used in human studies?
Most trials have used 250–1,000 mg per day, divided into one or two doses, for periods ranging from 4 to 12 weeks [PMID 35584623, PMID 39487653, PMID 40839339].
Does urolithin A improve muscle mass?
The studies to date report improvements in strength and performance rather than direct increases in muscle cross‑sectional area. No trial has shown a significant gain in lean mass over the short intervention periods used [PMID 39487653, PMID 40839339].
Can urolithin A replace exercise for muscle health?
No. All human trials combined UA supplementation with regular training, and the authors consistently note that exercise remains the primary driver of muscle adaptations. UA appears to augment, not replace, training effects [PMID 35584623, PMID 39487653].
Are there any safety concerns with urolithin A?
Across the published trials, UA was well tolerated with few adverse events. However, long‑term safety data are limited, and individuals with chronic medical conditions should consult a healthcare professional before starting supplementation.
Is urolithin A effective for women or older adults with frailty?
Most published trials have enrolled middle‑aged men or elite male athletes. One systematic review highlighted the paucity of data in women and frail older adults, calling for targeted research in these groups [3].
How quickly might someone notice performance benefits?
Improvements in strength or endurance have been reported after 4–6 weeks of daily supplementation in conjunction with training, but responses vary and are generally modest [PMID 35584623, PMID 39487653].
References
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Zhao H et al. Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. Journal of the International Society of Sports Nutrition (2024). PMID 39487653
- Whitfield J et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Sports medicine (Auckland, N.Z.) (2025). PMID 40839339
